CTI BIOPHARMA CORP

Form 4 May 27, 2016

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB Number:

3235-0287

0.5

Check this box if no longer

subject to Section 16. Form 4 or STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Expires: January 31, 2005 Estimated average

OMB APPROVAL

burden hours per response...

Form 4 or Form 5 obligations may continue. See Instruction

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

. .

1(b).

(Print or Type Responses)

| 1. Name and Address of Reporting Per BIANCO JAMES A | 2. Issuer Name and Ticker or Trading Symbol CTI BIOPHARMA CORP [ctic] | 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) | | |
|---|---|---|--|--|
| (Last) (First) (Mic | | | | |
| 3101 WESTERN AVE SUITE | (Month/Day/Year) 600 05/27/2016 | X Director 10% OwnerX Officer (give title Other (specify below) below) President and CEO | | |
| (Street) | 4. If Amendment, Date Original Filed(Month/Day/Year) | 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person | | |
| SEATTLE, WA 98121 (City) (State) (Zi | | Form filed by More than One Reporting Person | | |

| (213) | (State) | Tab | le I - Non-I | Derivative Secur | ities Acqui | red, Disposed of, | or Beneficiall | y Owned |
|-----------------|---------------------|--------------------|-----------------------------|--------------------|--------------|-------------------|----------------|--------------|
| 1.Title of | 2. Transaction Date | 2A. Deemed | 3. | 4. Securities Ac | quired (A) | 5. Amount of | 6. | 7. Nature of |
| Security | (Month/Day/Year) | Execution Date, if | Transaction Disposed of (D) | | | Securities | Ownership | Indirect |
| (Instr. 3) | | any | Code | (Instr. 3, 4 and 5 | 5) | Beneficially | Form: | Beneficial |
| | | (Month/Day/Year) | (Instr. 8) | | | Owned | Direct (D) | Ownership |
| | | | | | | Following | or Indirect | (Instr. 4) |
| | | | | (4) | | Reported | (I) | |
| | | | | (A) | | Transaction(s) | (Instr. 4) | |
| | | | Code V | Amount (D) | Price | (Instr. 3 and 4) | | |
| Common Stock | 05/27/2016 | | S <u>(1)</u> | 10,000 D | \$ 0.4471 | 1,790,133 | D | |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474

(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

Edgar Filing: CTI BIOPHARMA CORP - Form 4

| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transacti Code (Instr. 8) | Securities Acquired (A) or Disposed of (D) | | ate | Secur | int of rlying | 8. Price of Derivative Security (Instr. 5) | 9. Nu Deriv Secur Bene Owne Follo Repo Trans (Instr |
|---|---|---|---|---------------------------------------|--|---------------------|--------------------|-------|--|---|---|
| | | | | Code V | (Instr. 3, 4, and 5) (A) (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | | |

Reporting Owners

| Reporting Owner Name / Address | Keiauonsnips | | | | | |
|--------------------------------|--------------|-----------|-------------------|-------|--|--|
| | Director | 10% Owner | Officer | Other | | |
| BIANCO JAMES A | | | | | | |
| 3101 WESTERN AVE SUITE 600 | X | | President and CEO | | | |
| SEATTLE, WA 98121 | | | | | | |

Signatures

By: Louis A. Bianco, Attorney-in-fact For: James A. 05/27/2016 Bianco

> **Signature of Reporting Person Date

Explanation of Responses:

- If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The sale was effected pursuant to a Rule 10b5-1 trading plan.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Reporting Owners 2